Intron Biotechnology Stock Debt To Equity
| 048530 Stock | KRW 5,540 40.00 0.72% |
iNtRON Biotechnology fundamentals help investors to digest information that contributes to INtRON Biotechnology's financial success or failures. It also enables traders to predict the movement of INtRON Stock. The fundamental analysis module provides a way to measure INtRON Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to INtRON Biotechnology stock.
INtRON |
iNtRON Biotechnology Company Debt To Equity Analysis
INtRON Biotechnology's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current INtRON Biotechnology Debt To Equity | 10.90 % |
Most of INtRON Biotechnology's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, iNtRON Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, iNtRON Biotechnology has a Debt To Equity of 10.9%. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The debt to equity for all Republic of Korea stocks is notably lower than that of the firm.
INtRON Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses INtRON Biotechnology's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of INtRON Biotechnology could also be used in its relative valuation, which is a method of valuing INtRON Biotechnology by comparing valuation metrics of similar companies.INtRON Biotechnology is currently under evaluation in debt to equity category among its peers.
INtRON Fundamentals
| Return On Equity | 11.16 | |||
| Return On Asset | 0.0519 | |||
| Profit Margin | 0.34 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 734.71 B | |||
| Shares Outstanding | 29.88 M | |||
| Shares Owned By Insiders | 15.72 % | |||
| Shares Owned By Institutions | 8.10 % | |||
| Price To Earning | 313.17 X | |||
| Price To Sales | 9.32 X | |||
| Revenue | 29.31 B | |||
| Gross Profit | 26.45 B | |||
| EBITDA | 11.82 B | |||
| Net Income | 9.73 B | |||
| Cash And Equivalents | 75.17 B | |||
| Total Debt | 16.13 B | |||
| Debt To Equity | 10.90 % | |||
| Current Ratio | 3.71 X | |||
| Book Value Per Share | 2,284 X | |||
| Cash Flow From Operations | 16.47 B | |||
| Target Price | 16400.0 | |||
| Number Of Employees | 93 | |||
| Beta | 0.45 | |||
| Market Capitalization | 265.62 B | |||
| Total Asset | 153.37 B | |||
| Retained Earnings | 2.09 B | |||
| Working Capital | 14.29 B | |||
| Current Asset | 17.15 B | |||
| Current Liabilities | 2.86 B | |||
| Z Score | 9.6 | |||
| Net Asset | 153.37 B |
About INtRON Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze iNtRON Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INtRON Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of iNtRON Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with INtRON Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if INtRON Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in INtRON Biotechnology will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to INtRON Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace INtRON Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back INtRON Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling iNtRON Biotechnology to buy it.
The correlation of INtRON Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as INtRON Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if iNtRON Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for INtRON Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in INtRON Stock
INtRON Biotechnology financial ratios help investors to determine whether INtRON Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in INtRON with respect to the benefits of owning INtRON Biotechnology security.